Short communication: A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy

A recombinant fusion protein of colon carcinoma binding A33 single chain antibody with cytosine deaminase displayed specific antigen binding and enzyme activity in surface plasmon resonance and is catalytic activity assay. In vitro, it selectively increased the toxicity of 5-FC to A33 antigen-positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Deckert, P M, Renner, C, Cohen, L S, Jungbluth, A, Ritter, G, Bertino, J R, Old, L J, Welt, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377093/
https://www.ncbi.nlm.nih.gov/pubmed/12644833
http://dx.doi.org/10.1038/sj.bjc.6600751
_version_ 1782154775750508544
author Deckert, P M
Renner, C
Cohen, L S
Jungbluth, A
Ritter, G
Bertino, J R
Old, L J
Welt, S
author_facet Deckert, P M
Renner, C
Cohen, L S
Jungbluth, A
Ritter, G
Bertino, J R
Old, L J
Welt, S
author_sort Deckert, P M
collection PubMed
description A recombinant fusion protein of colon carcinoma binding A33 single chain antibody with cytosine deaminase displayed specific antigen binding and enzyme activity in surface plasmon resonance and is catalytic activity assay. In vitro, it selectively increased the toxicity of 5-FC to A33 antigen-positive cells by 300-fold, demonstrating the potency of this ADEPT strategy.
format Text
id pubmed-2377093
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23770932009-09-10 Short communication: A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy Deckert, P M Renner, C Cohen, L S Jungbluth, A Ritter, G Bertino, J R Old, L J Welt, S Br J Cancer Experimental Therapeutics A recombinant fusion protein of colon carcinoma binding A33 single chain antibody with cytosine deaminase displayed specific antigen binding and enzyme activity in surface plasmon resonance and is catalytic activity assay. In vitro, it selectively increased the toxicity of 5-FC to A33 antigen-positive cells by 300-fold, demonstrating the potency of this ADEPT strategy. Nature Publishing Group 2003-03-24 2003-03-18 /pmc/articles/PMC2377093/ /pubmed/12644833 http://dx.doi.org/10.1038/sj.bjc.6600751 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Experimental Therapeutics
Deckert, P M
Renner, C
Cohen, L S
Jungbluth, A
Ritter, G
Bertino, J R
Old, L J
Welt, S
Short communication: A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy
title Short communication: A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy
title_full Short communication: A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy
title_fullStr Short communication: A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy
title_full_unstemmed Short communication: A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy
title_short Short communication: A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy
title_sort short communication: a33scfv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy
topic Experimental Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377093/
https://www.ncbi.nlm.nih.gov/pubmed/12644833
http://dx.doi.org/10.1038/sj.bjc.6600751
work_keys_str_mv AT deckertpm shortcommunicationa33scfvcytosinedeaminasearecombinantproteinconstructforantibodydirectedenzymeprodrugtherapy
AT rennerc shortcommunicationa33scfvcytosinedeaminasearecombinantproteinconstructforantibodydirectedenzymeprodrugtherapy
AT cohenls shortcommunicationa33scfvcytosinedeaminasearecombinantproteinconstructforantibodydirectedenzymeprodrugtherapy
AT jungblutha shortcommunicationa33scfvcytosinedeaminasearecombinantproteinconstructforantibodydirectedenzymeprodrugtherapy
AT ritterg shortcommunicationa33scfvcytosinedeaminasearecombinantproteinconstructforantibodydirectedenzymeprodrugtherapy
AT bertinojr shortcommunicationa33scfvcytosinedeaminasearecombinantproteinconstructforantibodydirectedenzymeprodrugtherapy
AT oldlj shortcommunicationa33scfvcytosinedeaminasearecombinantproteinconstructforantibodydirectedenzymeprodrugtherapy
AT welts shortcommunicationa33scfvcytosinedeaminasearecombinantproteinconstructforantibodydirectedenzymeprodrugtherapy

Ejemplares similares